Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs
Upside potential from analyst upgrade.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Upside potential from analyst upgrade.
What happened, with direct paths to the underlying reporting
Goldman Sachs initiates Buy with a target of $116; current price around $74.29.
Target: $116
Posted price: $74.29
Analyst firm: Goldman Sachs
Analyst: Andrea Newkirk
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.